Clinical Trials Browser

Diffuse Intrinsic Pontine Glioma, Brain Neoplasms, Influenza, Human, Xanthomatosis, Cerebrotendinous

Glioblastoma

Carcinoma, Non-Small-Cell Lung

Glioblastoma, Tetanus

Ovarian Neoplasms

Neuroblastoma

Adenocarcinoma of Lung, Osteosarcoma

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Carcinoma, Renal Cell, Kidney Neoplasms

Multiple Myeloma, Neoplasms, Plasma Cell

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Carcinoma, Neoplasm Metastasis, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Recurrence

Osteosarcoma

Glioblastoma

Leukemia, Myelodysplastic Syndromes

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Rectal Neoplasms, Small Cell Lung Carcinoma

Unspecified Adult Solid Tumor, Protocol Specific

Neuroblastoma

Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Lymphoma, Lymphoma, T-Cell

Clinical Trials

ACTION

BRAVO

RENEW: Feasibility of CMV RNA-Pulsed Dendritic Cells Vaccines for the Treatment of Newly Diagnosed Glioblastoma Patients.

A Study of Sargramostim Plus Pembrolizumab with or Without Pemetrexed in Patients with Advance Non-small Cell Lung Cancer After Completion of Chemoimmunotherapy

I-ATTAC

Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer

NB2013-HR

IBI188 Combination Therapy in Solid Tumors

Vaccine Therapy in Treating Patients With Stage IIB, Stage III, or Stage IV Colorectal Cancer

Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma

Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and PEG-INTRON(R)

PEG-Interferon Alfa-2b, Sargramostim, and Thalidomide in Treating Patients With Metastatic Kidney Cancer

Trial of ID-Specific Donor Vaccinated Lymphocyte Infusion for Patients With Myeloma Relapsing or Failing to Achieve a Complete Remission After an Allogenic Transplant

CHOP-Rituximab Augmented With GM-CSF in Patients With Previously Untreated Diffuse Large B Cell Non-Hodgkin's Lymphoma

Phase II GM-CSF Plus Mitoxantrone in Hormone Refractory Prostate Cancer

Trial of GM-CSF Given in Combination With Ketoconazole and Mitoxantrone in Patients With Progressive Prostate Cancer

Safety and Efficacy Study of GM-CSF, Thalidomide Plus Docetaxel in Prostate Cancer

Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and GM-CSF in Treating Patients With Recurrent, Refractory, or Metastatic Non-Small Cell Lung Cancer

Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Sargramostim (GM-CSF) in Treating Advanced Solid Tumors

Doxorubicin With Cisplatin, High-Dose Methotrexate, and Additional Risk-Adapted Outpatient Chemotherapy

Peptide-based Glioma Vaccine IMA950 in Patients With Glioblastoma

Study of Azacytidine Followed by GM-CSF in Patients With Myelodysplastic Syndrome (MDS)

Vaccine Therapy and Sargramostim With or Without Docetaxel in Treating Patients With Metastatic Lung Cancer or Metastatic Colorectal Cancer

Vaccine Therapy With or Without Sargramostim in Treating Patients With Cancer

A Study of MAb-3F8 Plus Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus 13-cis-Retinoic Acid (RA) Plus GM-CSF in Primary Refractory Neuroblastoma Patients

Phase II Study of Fludarabine and Mitoxantrone, Followed by GM-CSF(Granulocyte-macrophage Colony-stimulating Factor) and Rituximab

Study of DT388GMCSF Fusion Protein in Acute Myelogenous Leukemia (AML) and Chronic Myelomonocytic Leukemia (CMML)

Autologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma